MGTA
Income statement / Annual
Last year (2022), Magenta Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Magenta Therapeutics, Inc.'s net income was -$72.02 M.
See Magenta Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$55.14 M
|
$46.77 M
|
$50.62 M
|
$59.21 M
|
$41.34 M
|
$27.90 M
|
$5.78 M
|
| General & Administrative
Expenses |
$25.76 M
|
$27.93 M
|
$28.09 M
|
$23.76 M
|
$18.62 M
|
$7.83 M
|
$3.49 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$25.76 M
|
$27.93 M
|
$28.09 M
|
$23.76 M
|
$18.62 M
|
$7.83 M
|
$3.49 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$80.90 M |
$74.69 M |
$78.70 M |
$82.97 M |
$59.96 M |
$35.73 M |
$9.27 M |
| Cost And Expenses |
$80.90 M |
$74.69 M |
$78.70 M |
$82.97 M |
$59.96 M |
$35.73 M |
$9.27 M |
| Interest Income |
$0.00 |
$3.56 M |
$3.77 M |
$0.00 |
$2.45 M |
$236,000.00 |
$0.00 |
| Interest Expense |
-$4.44 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$163,000.00 |
| Depreciation &
Amortization |
$1.93 M
|
$2.02 M
|
$1.98 M
|
$1.84 M
|
$875,000.00
|
$376,000.00
|
$6,000.00
|
| EBITDA |
-$78.98 M
|
-$74.69 M
|
-$78.70 M
|
-$82.97 M
|
-$59.96 M
|
-$35.12 M
|
-$9.26 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$4.44 M
|
$3.56 M
|
$3.77 M
|
$6.20 M
|
$2.45 M
|
$236,000.00
|
-$163,000.00
|
| Income Before Tax |
-$76.46 M |
-$71.14 M |
-$74.94 M |
-$76.77 M |
-$57.52 M |
-$35.49 M |
-$9.43 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$4.44 M |
-$5.58 M |
-$5.74 M |
-$8.04 M |
$2.45 M |
$236,000.00 |
$0.00 |
| Net Income |
-$72.02 M |
-$65.56 M |
-$69.19 M |
-$68.73 M |
-$57.52 M |
-$35.49 M |
-$9.43 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-23.05 |
-22.67 |
-29.93 |
-35.28 |
-59.42 |
-1.65 |
-0.44 |
| EPS Diluted |
-23.05 |
-22.67 |
-29.93 |
-35.28 |
-59.42 |
-1.65 |
-0.44 |
| Weighted Average Shares
Out |
$3.12 M
|
$2.89 M
|
$2.31 M
|
$1.95 M
|
$967,872.00
|
$21.50 M
|
$21.50 M
|
| Weighted Average Shares
Out Diluted |
$3.12 M
|
$2.89 M
|
$2.31 M
|
$1.95 M
|
$967,872.00
|
$21.50 M
|
$21.50 M
|
| Link |
|
|
|
|
|
|
|
